State of Tennessee Department of Treasury Lowers Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

State of Tennessee Department of Treasury cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,283 shares of the specialty pharmaceutical company's stock after selling 9,028 shares during the period. State of Tennessee Department of Treasury's holdings in Collegium Pharmaceutical were worth $237,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Franklin Resources Inc. boosted its stake in Collegium Pharmaceutical by 13.4% in the third quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock worth $1,164,000 after buying an additional 3,620 shares in the last quarter. Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after acquiring an additional 64,958 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after acquiring an additional 175,892 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 15.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 27,150 shares of the specialty pharmaceutical company's stock worth $778,000 after acquiring an additional 3,652 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.5 %

NASDAQ COLL opened at $27.78 on Tuesday. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The stock has a market capitalization of $892.63 million, a PE ratio of 11.97 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The business's 50-day moving average is $28.18 and its 200 day moving average is $30.23.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on COLL. Piper Sandler reduced their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now directly owns 124,421 shares of the company's stock, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares of the company's stock, valued at $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.